dabigatran has been researched along with arachidonic acid in 3 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (arachidonic acid) | Trials (arachidonic acid) | Recent Studies (post-2010) (arachidonic acid) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 19,295 | 486 | 3,040 |
| Protein | Taxonomy | dabigatran (IC50) | arachidonic acid (IC50) |
|---|---|---|---|
| 60 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 4.5 | |
| Fatty acid-binding protein, adipocyte | Homo sapiens (human) | 2.75 | |
| 10 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 4.5 | |
| 60 kDa chaperonin | Escherichia coli | 7.3 | |
| 10 kDa chaperonin | Escherichia coli | 7.3 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.0715 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.6026 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bode, C; Diehl, P; Meyer, M; Moser, M; Olivier, CB; Weber, S; Weik, P; Zhou, Q | 1 |
| Achilles, A; Dannenberg, L; Fischer, JW; Grandoch, M; Hohlfeld, T; Kelm, M; Levkau, B; Mohring, A; Polzin, A; Zeus, T | 1 |
| Cho, HJ; Choi, HY; Choi, S; Jang, HJ; Jang, SS; Jeon, S; Kim, DE; Kim, H; Kim, J; Kim, K; Kim, YD; Kwon, IC; Lee, KY; Lee, SK; Nahrendorf, M; Ryu, WS; Schellingerhout, D | 1 |
3 other study(ies) available for dabigatran and arachidonic acid
| Article | Year |
|---|---|
Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors.
Topics: Adenosine Diphosphate; Antithrombins; Arachidonic Acid; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Rivaroxaban; Ticlopidine | 2016 |
Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Arachidonic Acid; Atrial Fibrillation; Blood Platelets; Collagen; Cross-Sectional Studies; Dabigatran; Female; Flow Cytometry; Gene Expression Regulation; Humans; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Platelet Aggregation; Receptors, Thrombin; Regression Analysis; Risk Factors; Thrombin | 2017 |
Short-Term Cessation of Dabigatran Causes a Paradoxical Prothrombotic State.
Topics: Aged; Aged, 80 and over; Animals; Antithrombins; Arachidonic Acid; Aspirin; Carotid Artery Thrombosis; Cerebral Infarction; Chlorides; Computed Tomography Angiography; Dabigatran; Deprescriptions; Factor Xa Inhibitors; Female; Ferric Compounds; Humans; Ischemic Stroke; Magnetic Resonance Angiography; Male; Mean Platelet Volume; Mice; Noxae; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Substance Withdrawal Syndrome; Thrombin; Thrombophilia; X-Ray Microtomography | 2021 |